Phosphodiesterase type 5 inhibition may reduce diastolic function in women with ischemia but no obstructive coronary artery disease

Table 1 Patient characteristics, medical history, treatment history, and medication usage

	Patient #
	1	2	3	4	5
Age, years	55	67	56	65	82
Body mass index, kg/m²	23	26	21	29	19
Heart rate, bpm	53	63	80	48	41
Systolic blood pressure, mmHg	126	96	153	112	100
Diastolic blood pressure, mmHg	53	53	81	59	53
LV end-diastolic pressure, mmHg	15	17	---	20	---
Medical history
Hypertension	---	Y	Y	Y	Y
Dyslipidemia	Y	Y	---	Y	---
Diabetes mellitus	---	---	---	Y	---
Tobacco smoking	---	---	---	---	---
Myocardial infarction	---	---	---	Y	---
PDE5-inhibitor
Drug	Tadalafil	Tadalafil	Tadalafil	Sildenafil	Sildenafil
Dose	5 mg	20 mg	5 mg	20 mg TID	10 mg TID
Frequency	Every 3 days	Every 3 days	Every 3 days	Daily	Daily
Concomitant medications
Antiplatelet	Aspirin	Aspirin	Aspirin	Aspirin	Aspirin
Beta-blocker	Carvedilol	Atenolol	---	Carvedilol	Atenolol
Calcium channel blocker	---	---	Diltiazem	---	---
Statin	Pitavastatin	Rosuvastatin	---	Atorvastatin	---
Diuretic	---	HCTZ	---	---	HCTZ Furosemide
ACE-I/ARB	---	Ramipril	Losartan	Lisinopril	Losartan
Other	Levothyroxine	Amitriptyline	---	Metformin	Levothyroxine
Other	Prometrium (progesterone)	---	---	---	Dronedarone
Other	Estradiol	---	---	---	---

ACE-I/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, bpm beats per minute, HCTZ hydrochlorothiazide, LV left ventricular, PDE5 phosphodiesterase 5, TID three times a day, Y, Yes. Patient 5 was withdrawn by the investigators after developing dyspnea 1 week after treatment

ISSN: 1752-1947